迷幻药物与心理健康的科学研究
摘要
UCSF迷幻药物研究领域的领军人物 Dr. Robin Carhart-Harris 探讨了裸盖菇素、LSD和DMT等经典迷幻剂如何改变大脑连接性，以及这些变化与抑郁症、PTSD和其他精神科疾病治疗结果之间的关联。对话涵盖了临床试验结果、迷幻体验的机制、neuroplasticity，以及围绕微剂量与宏剂量的持续争议。
核心要点
- 裸盖菇素疗法在临床试验中对重度抑郁症达到约70%的应答率，远超传统抗抑郁药的疗效
- 主观体验在治疗中至关重要 —— 多项独立研究一致表明，迷幻旅程的强度可可靠地预测治疗结果
- 迷幻疗程中观察到的跨模块大脑连接性增强在次日仍持续存在，并可延续至三周后，且与抑郁症状改善程度相关
- 微剂量的证据薄弱：一项设计严谨的安慰剂对照研究发现，安慰剂效应（由预期心理驱动）可解释大部分所报告的获益
- “信任、放手、开放”治疗三原则是迷幻疗法的核心理念，治疗关系的质量可被量化地预测体验质量与治疗结果
- 音乐是所有已发表的主要迷幻疗法试验的标配成分，可能与药物产生协同作用，增强情绪处理
- 疗程后的整合工作 —— 通过心理治疗、日记、冥想或正念练习 —— 至关重要，且可能需要作为持续性实践长期坚持
- 裸盖菇素疗法在神经性厌食症治疗方面已显示出早期令人鼓舞的结果，而厌食症是致死率最高的精神科疾病之一
- 生物技术公司正在开发的非致幻性迷幻药类似物受到质疑，因为具有宣泄性、揭示内心的体验过程可能是其治疗机制的核心
详细笔记
什么是迷幻药？
*迷幻药（psychedelic）*一词由英国精神科医师 Humphry Osmond 于1956年根据两个古希腊词根创造：
- Psyche —— 心灵或灵魂
- Delos —— 使显现、揭示
Osmond 创造该词是为了替代 psychotomimetic（模拟精神病的药物），他认为后者未能充分描述这类体验的完整本质。这一术语在情感价值上保持中立 —— 它不暗示好或坏的体验，仅表示心灵的某些层面得以显现。
从药理学角度看，经典迷幻剂（裸盖菇素、LSD、DMT、麦司卡林）的定义特征在于其对 serotonin 2A receptor 的作用。然而，Dr. Carhart-Harris 认为主观体验不可与其定义相分离。
剂量校准：裸盖菇素
- 粗略换算：干蘑菇质量的约1%为裸盖菇素/脱磷裸盖菇素，因此 1克蘑菇 ≈ 10毫克裸盖菇素
- 临床试验剂量：
- 25毫克裸盖菇素 —— 完整宏剂量，产生强烈迷幻效果
- 10毫克裸盖菇素 —— 中等剂量
- 1毫克裸盖菇素 —— 功能性安慰剂；EEG上无可测量的大脑变化
- LSD微剂量阈值：约10–12微克（对大多数人而言低于感知阈值）
微剂量：证据的真实面貌
- 微剂量是指按某一周期（如隔天或每三天一次）服用低于感知阈值的迷幻剂（如LSD或裸盖菇素）
- 现有证据薄弱 —— 没有令人信服的安慰剂对照数据支持其认知或情绪获益
- 一项创意性公民科学研究（Szigeti等人，Imperial College）让参与者使用不透明胶囊和二维码对自己的LSD微剂量进行盲法处理
- 结果：安慰剂的效果与活性微剂量相当
- 该效应主要由积极预期驱动，而非药物本身
- 新西兰一项待发表的随机对照试验显示情绪有初步改善，但尚未经过同行评审
迷幻旅程：阶段与治疗机制
临床试验中的情境设置：
- 患者躺在沙发或床上，佩戴眼罩
- 全程有两位治疗师陪同（理想情况下为持牌心理健康专业人员）
- 全程播放音乐 —— 开始时空灵舒缓，随后情感强度逐渐增强；起初无歌词
体验阶段（基于 Harry Brouwer 的研究）：
- 早期阶段：以焦虑、迷失方向、对死亡或失去理智的恐惧为主 —— 被描述为自我溶解的基本药物作用
- 后期阶段：情绪释放、内省洞见、积极情感，以及常见的宣泄
核心治疗原则 —— “信任、放手、开放”：
- 归功于迷幻疗法先驱 Bill Richards
- 信任：在用药当天早晨测量的治疗关系质量，可预测数周后的体验质量和治疗结果
- 放手：测量得到的顺从意愿可预测治疗反应
- 开放：面对困难素材（包括创伤）的意愿
大脑机制：连接性与神经可塑性
迷幻疗程期间：
- 经典迷幻剂可产生显著的全脑functional connectivity增强 —— 通常只在本模块内通讯的脑区开始跨模块通讯
- 这种模块化程度下降与主观体验强度相关
- 已在裸盖菇素、LSD和DMT的fMRI研究中重复验证
疗程结束后：
- 在抑郁症队列中，残余增强的连接性于次日仍可观察到
- 在后续一项独立研究中，三周后仍然存在
- 连接性变化的幅度与抑郁症状改善程度相关
结构性大脑变化（来自健康志愿者研究的新未发表数据）：
- 使用弥散张量成像（白质纤维束分析），在连接以下脑区的主要纤维束中发现了解剖学变化：
- 前额叶皮层 ↔ 丘脑
- 前额叶皮层 ↔ 纹状体
- 这些结构变化仅在25毫克裸盖菇素组中出现，安慰剂组未见
熵脑效应：
- EEG记录显示裸盖菇素可增加大脑活动的信息复杂性 —— 脑活动模式变得更难预测，信息量更为丰富
- 与体验的主观强度成比例
迷幻疗法 vs. SSRI药物治疗
在一项发表于《新英格兰医学杂志》的里程碑式研究中，裸盖菇素疗法与 escitalopram（Lexapro） 进行了比较：
- 裸盖菇素：两次25毫克疗程，间隔三周
- Escitalopram：每日用药六周，另加1毫克裸盖菇素（功能性安慰剂）
- 两组心理治疗方案相同
- 裸盖菇素疗法在多项指标上显示出更优越的结果
核心概念区别：
- SSRI = “坐压”情绪（长期抑制）
- 迷幻疗法 = “与”情绪”同坐”（处理与整合）
整合：疗程结束后的工作
- 整合是指将迷幻体验中的洞见与改变巩固为持久的行为和心理转变
- 治疗团队通常在用药后数周内为患者提供整合支持
- 长期整合可能需要持续的个人实践，类似于冥想练习
- 正念与冥想被视为重要的辅助手段 —— 培养在不产生反应性的情况下观察内在困难状态的能力
- “迷幻实践”（类比冥想实践）的概念正作为一种维持长期获益的框架逐渐兴起
抑郁症之外的应用
- PTSD：MDMA辅助疗法（并非经典迷幻剂，但常被归为同类）使患者能够以降低的恐惧反应面对创伤
- 神经性厌食症：正在进行的裸盖菇素试验（3次疗程，间隔约2周）在随访中显示与食物相关的强迫性思维及体重方面有初步改善 —— 鉴于厌食症是致死率最高的精神科疾病，这一结果意义重大
- 健康个体：对迷幻药物初次接触的中年受试者给予裸盖菇素（25毫克），其心理健康水平显示出显著改善
English Original 英文原文
The Science of Psychedelics for Mental Health
Summary
Dr. Robin Carhart-Harris, a leading psychedelics researcher at UCSF, discusses how classic psychedelics like psilocybin, LSD, and DMT alter brain connectivity and how these changes relate to therapeutic outcomes in depression, PTSD, and other psychiatric conditions. The conversation covers clinical trial results, the mechanics of the psychedelic experience, neuroplasticity, and the ongoing debate around microdosing versus macrodosing.
Key Takeaways
- Psilocybin therapy achieved ~70% response rates for major depression in clinical trials, far exceeding typical antidepressant outcomes
- The subjective experience matters therapeutically — the magnitude of the psychedelic journey reliably predicts therapeutic outcomes across independent studies
- Increased cross-modular brain connectivity observed during a psychedelic session persists the next day and up to three weeks later, correlating with depression symptom improvement
- Microdosing evidence is weak: a well-designed placebo-controlled study found that the placebo response (driven by expectancy) explained most of the reported benefits
- The therapeutic triad of “trust, let go, be open” is a core principle in psychedelic therapy, with therapeutic rapport measurably predicting experience quality and outcomes
- Music is a staple component of all major published psychedelic therapy trials and may synergize with the drug to amplify emotional processing
- Integration after the session — through therapy, journaling, meditation, or mindfulness practice — is essential and may need to continue long-term as an ongoing practice
- Psilocybin therapy is showing early promising results for anorexia nervosa, one of the deadliest psychiatric illnesses
- Non-hallucinogenic psychedelic analogs being developed by biotech companies are viewed skeptically, as the cathartic, psyche-revealing experience may be central to the therapeutic mechanism
Detailed Notes
What Are Psychedelics?
The word psychedelic was coined by British psychiatrist Humphry Osmond in 1956 from two ancient Greek roots:
- Psyche — mind or soul
- Delos — to make visible, to reveal
Osmond coined it as an alternative to psychotomimetic (drugs that mimic psychosis), feeling the term failed to capture the fuller nature of the experience. The term is intentionally valence-neutral — it does not imply a good or bad experience, only that aspects of the mind are revealed.
Pharmacologically, classic psychedelics (psilocybin, LSD, DMT, mescaline) are defined by their action at the serotonin 2A receptor. However, Dr. Carhart-Harris argues the subjective experience cannot be separated from the definition.
Dosage Calibration: Psilocybin
- Rough conversion: ~1% of dried mushroom mass is psilocybin/psilocin, so 1 gram of mushrooms ≈ 10 mg of psilocybin
- Clinical trial doses:
- 25 mg psilocybin — full macrodose, produces strong psychedelic effects
- 10 mg psilocybin — moderate dose
- 1 mg psilocybin — functionally a placebo; no measurable brain changes on EEG
- LSD microdose threshold: approximately 10–12 micrograms (sub-perceptual for most people)
Microdosing: What the Evidence Actually Shows
- Microdosing involves taking sub-perceptual doses of a psychedelic (e.g., LSD or psilocybin) on a schedule such as every other day or every third day
- Current evidence is weak — no compelling placebo-controlled data supports cognitive or mood benefits
- A creative citizen science study (Szigeti et al., Imperial College) had participants blind their own LSD microdoses using opaque capsules and QR codes
- Result: Placebo performed as well as the active microdose
- The effect was largely driven by positive expectancy, not the drug itself
- A pending New Zealand randomized controlled trial shows preliminary improvements in mood but has not yet been peer-reviewed
The Psychedelic Journey: Phases and Therapeutic Mechanisms
Set and setting in clinical trials:
- Patients lie on a sofa or bed, wearing eye masks
- Two therapists present throughout (ideally licensed mental health professionals)
- Music played throughout — starting spacious and building in emotional intensity; no lyrics initially
Phases of the experience (based on research by Harry Brouwer):
- Early phase: dominated by anxiety, disorientation, fear of death or loss of sanity — described as a basic drug action of ego dissolution
- Later phase: emotional release, insight, positive affect, and often catharsis
Key therapeutic principle — “Trust, Let Go, Be Open”:
- Attributed to psychedelic therapy pioneer Bill Richards
- Trust: Therapeutic rapport measured the morning of dosing predicts experience quality and outcomes weeks later
- Let go: Measured willingness to surrender predicts therapeutic response
- Be open: Willingness to confront difficult material, including trauma
Brain Mechanisms: Connectivity and Neuroplasticity
During the psychedelic session:
- Classic psychedelics produce a dramatic increase in global functional connectivity — brain regions that normally communicate within their own module begin communicating across modules
- This decrease in modularity correlates with the intensity of subjective effects
- Replicated across psilocybin, LSD, and DMT using fMRI
After the session:
- Residual increased connectivity observed the next day in depression cohorts
- Still present at three weeks in a subsequent independent study
- The magnitude of connectivity change correlates with symptom improvement in depression
Structural brain changes (new unpublished data from healthy volunteers study):
- Using diffusion tensor imaging (white matter tract analysis), anatomical changes were found in major fiber tracts connecting:
- Prefrontal cortex ↔ Thalamus
- Prefrontal cortex ↔ Striatum
- These structural changes were seen only with 25 mg psilocybin, not placebo
The Entropic Brain Effect:
- EEG recordings show psilocybin increases the informational complexity of brain activity — patterns become less predictable and more informationally rich
- Scales with subjective intensity of the experience
Psychedelic Therapy vs. SSRI Pharmacotherapy
In a landmark study published in the New England Journal of Medicine, psilocybin therapy was compared to escitalopram (Lexapro):
- Psilocybin: two sessions of 25 mg, three weeks apart
- Escitalopram: six weeks of daily dosing plus 1 mg psilocybin (functional placebo)
- Psychotherapy standardized across both arms
- Psilocybin therapy showed superior results on several measures
Key conceptual distinction:
- SSRIs = “sit on” emotions (chronic suppression)
- Psychedelic therapy = “sit with” emotions (processing and integration)
Integration: What Happens After the Session
- Integration refers to consolidating insights and changes from the psychedelic experience into lasting behavioral and psychological shifts
- The therapeutic team typically supports integration in the weeks following dosing
- Long-term integration may require ongoing personal practice analogous to meditation
- Mindfulness and meditation are seen as important complements — training the capacity to observe difficult internal states without reactivity
- The concept of a “psychedelic practice” (like a meditation practice) is emerging as a framework for sustained benefit
Applications Beyond Depression
- PTSD: MDMA-assisted therapy (not a classic psychedelic but often grouped alongside) enables patients to approach trauma with reduced fear response
- Anorexia nervosa: Ongoing psilocybin trial (3 sessions, ~2 weeks apart) showing preliminary improvements in obsessive food-related thinking and weight at follow-up — significant given anorexia’s status as the deadliest psychiatric illness
- Healthy individuals: Psilocybin (25 mg) in psychedelic-naive middle-aged subjects showed significant improvements in psychological well-being